NuVasive, Inc. delivered third-quarter 2019 adjusted earnings per share (EPS) of 59 cents, reflecting a 5.4% rise from the year-ago quarter. The figure also surpassed the Zacks Consensus Estimate by 9.3%. On a reported basis, EPS came in at 21 cents, highlighting a 30% decline from the year-ago number.
Revenues in the third quarter totaled $290.8 million, up 7.2% on a reported basis (up 7.5% at constant exchange rate or CER) year over year. The top line also beat the Zacks Consensus Estimate by 2.4%.
Geographical & Segmental Details
In the quarter under review, revenues at the U.S. Spinal Hardware business increased 9.5% year over year to $160 million. The upside was driven by solid uptick in case volume and tangible growth in both the XLIF and ALIF franchises, led by continued adoption of NuVasive's X360 system.
Revenues in the U.S. Surgical Support business were $71.9 million in the third quarter, down nearly 1% year over year. Within the Biologics segment, there was a 1% revenue decline from the year-ago quarter.
In the third quarter, the company registered international revenues of $59 million, reflecting 13.4% year-over-year growth at CER. The EMEA region witnessed a solid uptick, driven by substantial contribution from the United Kingdom and Spain. This was offset by sluggish growth in Asia Pacific and Latin America.
Margin Details
In the reported quarter, gross profit improved 8.5% year over year to $213.8 million. Gross profit margin expanded 85 basis points (bps) to 73.5%. Adjusted operating profit fell 2.8% from the year-ago period to $14 million. Accordingly, adjusted operating margin contracted 50 bps to 4.8% in the quarter under review.
Operational Update
The company exited the third quarter of 2019 with cash and cash equivalents of $163.4 million, compared with $128.4 million at the end of the second quarter. Year to date, net cash provided by operating activities totaled $160.6 million, compared with $150.5 million a year ago.
Guidance for 2019
NuVasive currently projects revenues for 2019 at the high end of the previously-projected range of $1.14-$1.16 billion. The Zacks Consensus Estimate for 2019 revenues is pegged at $1.15 billion, below the company’s guidance. However, the company raised its 2019 adjusted EPS to $2.35 to $2.40, compared with the prior guidance of $2.25 to $2.35. The Zacks Consensus Estimate for this metric stands at $2.32, below the guided range.
Our Take
NuVasive exited the third quarter of 2019 on a promising note. We are encouraged to note that the company witnessed solid revenue growth across its U.S. Spinal Hardware business, driven by increased surgeon adoption of lateral single-position surgery and X360 system. Robust sales figures in some of the key international markets buoy optimism. On the flip side, the slight revenue decline within the U.S. Surgical Support and Biologics segments and contraction in adjusted operating margin were disappointing.
Earnings of Other MedTech Majors at a Glance
NuVasive carries a Zacks Rank #2 (Buy).
Some other top-ranked companies, which posted solid results this earnings season, are Edwards Lifesciences (EW - Free Report) , Thermo Fisher Scientific (TMO - Free Report) and ResMed (RMD - Free Report) , each carrying a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Edwards Lifesciences delivered third-quarter 2019 adjusted EPS of $1.41, outpacing the Zacks Consensus Estimate by 15.6%. Net sales of $1.09 billion surpassed the Zacks Consensus Estimate by 5.5%.
Thermo Fisher delivered third-quarter 2019 adjusted EPS of $2.94, which surpassed the Zacks Consensus Estimate by 2.1%. Revenues of $6.27 billion outpaced the consensus estimate by 1.3%.
ResMed reported first-quarter fiscal 2020 adjusted EPS of 93 cents, which beat the Zacks Consensus Estimate of 87 cents by 6.9%. Revenues were $681.1 million, surpassing the Zacks Consensus Estimate by 3.6%.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.5% per year. So be sure to give these hand-picked 7 your immediate attention.
See them now >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
NuVasive, Inc. delivered third-quarter 2019 adjusted earnings per share (EPS) of 59 cents, reflecting a 5.4% rise from the year-ago quarter. The figure also surpassed the Zacks Consensus Estimate by 9.3%. On a reported basis, EPS came in at 21 cents, highlighting a 30% decline from the year-ago number.
Revenues in the third quarter totaled $290.8 million, up 7.2% on a reported basis (up 7.5% at constant exchange rate or CER) year over year. The top line also beat the Zacks Consensus Estimate by 2.4%.
Geographical & Segmental Details
In the quarter under review, revenues at the U.S. Spinal Hardware business increased 9.5% year over year to $160 million. The upside was driven by solid uptick in case volume and tangible growth in both the XLIF and ALIF franchises, led by continued adoption of NuVasive's X360 system.
Revenues in the U.S. Surgical Support business were $71.9 million in the third quarter, down nearly 1% year over year. Within the Biologics segment, there was a 1% revenue decline from the year-ago quarter.
In the third quarter, the company registered international revenues of $59 million, reflecting 13.4% year-over-year growth at CER. The EMEA region witnessed a solid uptick, driven by substantial contribution from the United Kingdom and Spain. This was offset by sluggish growth in Asia Pacific and Latin America.
Margin Details
In the reported quarter, gross profit improved 8.5% year over year to $213.8 million. Gross profit margin expanded 85 basis points (bps) to 73.5%. Adjusted operating profit fell 2.8% from the year-ago period to $14 million. Accordingly, adjusted operating margin contracted 50 bps to 4.8% in the quarter under review.
Operational Update
The company exited the third quarter of 2019 with cash and cash equivalents of $163.4 million, compared with $128.4 million at the end of the second quarter. Year to date, net cash provided by operating activities totaled $160.6 million, compared with $150.5 million a year ago.
Guidance for 2019
NuVasive currently projects revenues for 2019 at the high end of the previously-projected range of $1.14-$1.16 billion. The Zacks Consensus Estimate for 2019 revenues is pegged at $1.15 billion, below the company’s guidance. However, the company raised its 2019 adjusted EPS to $2.35 to $2.40, compared with the prior guidance of $2.25 to $2.35. The Zacks Consensus Estimate for this metric stands at $2.32, below the guided range.
Our Take
NuVasive exited the third quarter of 2019 on a promising note. We are encouraged to note that the company witnessed solid revenue growth across its U.S. Spinal Hardware business, driven by increased surgeon adoption of lateral single-position surgery and X360 system. Robust sales figures in some of the key international markets buoy optimism. On the flip side, the slight revenue decline within the U.S. Surgical Support and Biologics segments and contraction in adjusted operating margin were disappointing.
Earnings of Other MedTech Majors at a Glance
NuVasive carries a Zacks Rank #2 (Buy).
Some other top-ranked companies, which posted solid results this earnings season, are Edwards Lifesciences (EW - Free Report) , Thermo Fisher Scientific (TMO - Free Report) and ResMed (RMD - Free Report) , each carrying a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Edwards Lifesciences delivered third-quarter 2019 adjusted EPS of $1.41, outpacing the Zacks Consensus Estimate by 15.6%. Net sales of $1.09 billion surpassed the Zacks Consensus Estimate by 5.5%.
Thermo Fisher delivered third-quarter 2019 adjusted EPS of $2.94, which surpassed the Zacks Consensus Estimate by 2.1%. Revenues of $6.27 billion outpaced the consensus estimate by 1.3%.
ResMed reported first-quarter fiscal 2020 adjusted EPS of 93 cents, which beat the Zacks Consensus Estimate of 87 cents by 6.9%. Revenues were $681.1 million, surpassing the Zacks Consensus Estimate by 3.6%.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.5% per year. So be sure to give these hand-picked 7 your immediate attention.
See them now >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on TMO - FREE
Get the latest research report on EW - FREE
Get the latest research report on RMD - FREE